266 related articles for article (PubMed ID: 26766496)
1. Emerging therapeutic targets and strategies in Crohn's disease.
Furfaro F; Fiorino G; Allocca M; Gilardi D; Danese S
Expert Rev Gastroenterol Hepatol; 2016 Jun; 10(6):735-44. PubMed ID: 26766496
[TBL] [Abstract][Full Text] [Related]
2. Cytokine therapies in Crohn's disease: where are we now and where should we go?
Caprioli F; Pallone F; Monteleone G
Inflamm Allergy Drug Targets; 2011 Feb; 10(1):47-53. PubMed ID: 21184652
[TBL] [Abstract][Full Text] [Related]
3. Controlling leukocyte trafficking in IBD.
Veny M; Fernández-Clotet A; Panés J
Pharmacol Res; 2020 Sep; 159():105050. PubMed ID: 32598943
[TBL] [Abstract][Full Text] [Related]
4. Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases.
Billmeier U; Dieterich W; Neurath MF; Atreya R
World J Gastroenterol; 2016 Nov; 22(42):9300-9313. PubMed ID: 27895418
[TBL] [Abstract][Full Text] [Related]
5. Role of the IL23/IL17 Pathway in Crohn's Disease.
Schmitt H; Neurath MF; Atreya R
Front Immunol; 2021; 12():622934. PubMed ID: 33859636
[TBL] [Abstract][Full Text] [Related]
6. Mucosal healing in pediatric Crohn's disease after anti-TNF therapy: a long-term experience at a single center.
Nobile S; Gionchetti P; Rizzello F; Calabrese C; Campieri M
Eur J Gastroenterol Hepatol; 2014 Apr; 26(4):458-65. PubMed ID: 24445727
[TBL] [Abstract][Full Text] [Related]
7. How should we treat mild and moderate-severe Crohn's disease in 2017? A brief overview of available therapies.
Winter RW; Burakoff R
Expert Rev Gastroenterol Hepatol; 2017 Feb; 11(2):95-97. PubMed ID: 27900879
[No Abstract] [Full Text] [Related]
8. Nuclear factor-κB - importance, induction of inflammation, and effects of pharmacological modulators in Crohn's disease.
Szatkowski P; Krzysciak W; Mach T; Owczarek D; Brzozowski B; Szczeklik K
J Physiol Pharmacol; 2020 Aug; 71(4):. PubMed ID: 33214334
[TBL] [Abstract][Full Text] [Related]
9. Ustekinumab for the treatment of Crohn's disease.
Hansen T; Targownik LE
Expert Rev Gastroenterol Hepatol; 2016 Sep; 10(9):989-94. PubMed ID: 27450626
[TBL] [Abstract][Full Text] [Related]
10. Damage-associated molecular patterns in inflammatory bowel disease: From biomarkers to therapeutic targets.
Nanini HF; Bernardazzi C; Castro F; de Souza HSP
World J Gastroenterol; 2018 Nov; 24(41):4622-4634. PubMed ID: 30416310
[TBL] [Abstract][Full Text] [Related]
11. Targeting Specific Immunologic Pathways in Crohn's Disease.
Ramos GP; Faubion WA; Papadakis KA
Gastroenterol Clin North Am; 2017 Sep; 46(3):577-588. PubMed ID: 28838416
[TBL] [Abstract][Full Text] [Related]
12. Mucosal expression of basic fibroblastic growth factor, syndecan 1 and tumour necrosis factor-α in Crohn's disease in deep remission under treatment with anti-TNFα antibodies.
Tursi A; Elisei W; Principi M; Inchingolo CD; Nenna R; Picchio M; Giorgio F; Ierardi E; Brandimarte G
J Gastrointestin Liver Dis; 2014 Sep; 23(3):261-5. PubMed ID: 25267953
[TBL] [Abstract][Full Text] [Related]
13. Inflammatory pathways of importance for management of inflammatory bowel disease.
Pedersen J; Coskun M; Soendergaard C; Salem M; Nielsen OH
World J Gastroenterol; 2014 Jan; 20(1):64-77. PubMed ID: 24415859
[TBL] [Abstract][Full Text] [Related]
14. How to manage difficult Crohn's disease: optimum delivery of anti-TNFs.
Krygier DS; Ko HH; Bressler B
Expert Rev Gastroenterol Hepatol; 2009 Aug; 3(4):407-15. PubMed ID: 19673627
[TBL] [Abstract][Full Text] [Related]
15. Vedolizumab in the treatment of Crohn's disease.
Tarabar D; Hirsch A; Rubin DT
Expert Rev Gastroenterol Hepatol; 2016; 10(3):283-90. PubMed ID: 26810276
[TBL] [Abstract][Full Text] [Related]
16. The role of genetics in Crohn's disease: how could it influence future therapies?
Geremia A; Satsangi J
Expert Rev Gastroenterol Hepatol; 2018 Nov; 12(11):1075-1077. PubMed ID: 30124365
[No Abstract] [Full Text] [Related]
17. Potential therapeutic role for cytokine or adhesion molecule manipulation in Crohn's disease: in the shadow of infliximab?
Shand A; Forbes A
Int J Colorectal Dis; 2003 Jan; 18(1):1-11. PubMed ID: 12458374
[TBL] [Abstract][Full Text] [Related]
18. Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases.
Danese S; Panés J
Gastroenterology; 2014 Nov; 147(5):981-9. PubMed ID: 25220794
[TBL] [Abstract][Full Text] [Related]
19. Emerging drugs to treat Crohn's disease.
Strauch U; Schölmerich J
Expert Opin Emerg Drugs; 2010 Jun; 15(2):309-22. PubMed ID: 20402560
[TBL] [Abstract][Full Text] [Related]
20. Focus on mechanisms of inflammation in inflammatory bowel disease sites of inhibition: current and future therapies.
Van Assche G; Vermeire S; Rutgeerts P
Gastroenterol Clin North Am; 2006 Dec; 35(4):743-56. PubMed ID: 17129811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
